CSF - VictoryShares US Discovery Enhanced Volatility Wtd ETF 0 WATCHERS

Gain Therapeutics ($GANX) — quietly emerging as one of the most compelling Parkinson’s stories in biotech. **The set-up that Gain Therapeutics has right now is extremely rare, IMO. Largely de-risked, and is only a week or two away from releasing what is likely some of the most compelling evidence of …

GANX Gain Therapeutics with December Parkinson’s Data There have been multiple recent posts on Gain Therapeutics and that they will be releasing in December additional Phase 1b data. So far from the Phase 1b 90 day trial of 16 patients we have seen UPDRS scores on 9 of them. These …

PSTV News - National Coverage Agreement This News was shared just recently, you may need to take a look! Plus" or the "Company"), announced today that it has signed a national agreement with Humana, Inc. (NYSE:HUM), effective October 29, 2025, covering approximately 16 million people throughout the United States, to …

PSTV 🚀🚀🚀 CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a national agreement with Humana, Inc. (NYSE: HUM), effective October 29, 2025, covering approximately 16 million people throughout the United States, to provide the CNSide® Cerebrospinal …